Clinical Trial Update: Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating a CD4-targeted CAR T cell therapy for relapsed/refractory acute myeloid leukemia as a bridge to allogeneic stem cell transplan…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CD4-targeted CAR T cell therapy

Snippet

Sponsor: Huda Salman | Conditions: Acute Myeloid Leukemia | Phase 1 | Status: RECRUITING